Follow

Last day of the subscription period for warrants Cline TO 1 B is March 12 2021

11 March 2021 - 09:57

Friday March 12, 2021 is the last day of the exercise period of series 2020/2021 in Cline Scientific AB (publ) (“Cline” or “the Company”). Each warrant gives the right to subscribe for one (1) new share in Cline Scientific. The exercise price for the warrants is SEK 3.38 per share. The exercise period lasts until Friday March 12, 2021.

Holders of warrants who wish to convert these to shares must register no later than Friday, March 12, 2021.

Our intention is that all option holders will have the chance to convert their options into shares. If for any reason you have not received an application form, please contact Cline Scientific and we will help you with the process, see contact information below.

How the warrants are exercised:

Nominee-registered warrants (custody)
Nominee-registered holders of warrants must notify redemption of warrants by contacting their nominee and following their nominee's instructions regarding payment, etc. This should be done well in advance of 12 March 2021, when different nominees have different processing times. Subscription and payment of new shares through the exercise of warrants shall take place in accordance with instructions from the respective nominee. Please contact your trustee for further information.

Directly registered warrants (VP ​​account)
Application form and information has been sent to warrant holders. Subscription must be made by simultaneous cash payment according to the instructions on the application form. The warrants are then replaced with interim shares (IA) until registration is completed with the Swedish Companies Registration Office, after which interim shares are automatically exchanged for ordinary shares in Cline Scientific.

Application form with instructions for payment is available on the Company's website www.clinescientific.com and on Aktieinvest FK AB's website https://www.aktieinvest.se/.

Full terms for the warrants were included as part of the memorandum published in connection with the rights issue, which was published on May 8, 2020. The memorandum is available at www.clinescientific.com.

For more information, please contact:
Patrik Sundh, CEO
Email: [email protected]
Phone: +46 703-585 088

Cline Scientific AB (publ)                                                 Phone: 031-387 55 55
Argongatan 2 C                                                                   Email: [email protected]
431 53  MÖLNDAL                                                              Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
Cline Scientific AB
Cline Scientific develops and markets products for biomedical research based on proprietary nanotechnology. Its products include unique surfaces for use in stem cell & cancer research and customized nanoparticles for use in biomedical applications....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More